论文部分内容阅读
对于有发生卒中危险的患者,可供选择的预防药物很少。Ticlopidine(TP,噻氯匹啶)是一种有抗血栓作用的血小板抑制剂,70年代中叶起已被广泛研究和应用。加拿大-美国 TP 研究组织(CATS)和 TP-As-pirin 卒中研究组织(TASS)为 TP 预防卒中的功效和安全性提供了可靠资料。CATS 以双盲法用 TP(250mg,bid)或安慰剂对1053例缺血性卒中患者进行预防,TP 组卒中发生率和死亡率明显降低(P=0.008)。TASS 以双盲法用 TP(250mg,bid)或ASA(阿司匹林650mg,bid)对3069例短暂性脑缺
There are few alternative prophylactic drugs for patients at risk of stroke. Ticlopidine (TP, ticlopidine) is an anti-thrombotic platelet inhibitor, since the mid-70s has been widely studied and applied. Canada - The United States TP Research Group (CATS) and the TP-As-pirin Stroke Research Organization (TASS) provided reliable information on the efficacy and safety of TP in stroke prevention. In the CATS, 1053 patients with ischemic stroke were treated with either TP (250 mg bid) or placebo for a double-blind strategy. The incidence of stroke and mortality in the TP group were significantly lower (P = 0.008). TASS A total of 3069 patients with transient brain ablation were treated with TP (250 mg bid) or ASA (aspirin 650 mg bid) in a double-blind fashion